Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI)

Affiliations

• ¹ Department of Medicine, University of Virginia, Charlottesville (A.A., A.T.).
• ² Department of Internal Medicine, Virginia Commonwealth University, Richmond (B.V.T., R.M.).
• ³ Cromos Pharma, LLC, Portland, OR (V.B.).
• ⁴ Emergency Cardiology Department, National Medical Research Center for Cardiology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia (D.V. Pevzner).
• ⁵ Department of Cardiovascular Medicine Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH (P.C.C.).
• ⁶ Department of Internal Medicine, Peoples' Friendship University of Russia n.a. Patrice Lumumba, Moscow (I.M.).
• ⁷ Cardiology and Intensive Therapy Department, City Clinical Hospital No. 51 of Moscow Healthcare Department, Russia (D.V. Privalov).
• ⁸ R-Pharm JSC, Medical Department, Moscow, Russia (S.A.G., A.N.E., E.G.P., M.Y.S.).
• ⁹ R-Pharm Overseas Inc, La Jolla, CA (Y.L.).